Enlicitide lowered bad cholesterol across cardiovascular risk groups
A pooled analysis of two randomized trials in 3,212 people found lower bad cholesterol with enlicitide than placebo across cardiovascular risk groups.
Randomized trial, double-blind, placebo-controlled
Limit: The conference abstract did not report harms
Edited by Boris Djordjevic · AgingResearch.News
The pooled analysis covered 3,212 participants in two randomized, double-blind, placebo-controlled trials. Their mean age was 61.8 years, and 40.4% were women. Most had high or very high cardiovascular risk. The trials compared enlicitide, taken at 20 mg once daily, with placebo.
At 24 weeks, enlicitide reduced low-density lipoprotein (LDL) cholesterol, often called “bad” cholesterol, across the cardiovascular risk categories compared with placebo. Reductions persisted at 52 weeks. More participants taking enlicitide reached LDL cholesterol targets at 24 weeks. Goals for apolipoprotein B, a protein in cholesterol-carrying particles, were reached by 81% taking enlicitide versus 16% taking placebo in the very-high-risk group, and by 84% versus 22% in the high-risk group at 24 weeks.
Why it matters
Cardiovascular disease is an age-related health concern. The analysis addressed whether an oral drug could help people at different risk levels reach guideline cholesterol targets.
Caveats
The reported results concerned blood measures, not whether enlicitide reduced heart attacks or strokes. The conference abstract did not report harms, and most participants had high or very high cardiovascular risk.
The paper
Efficacy of enlicitide across ESC cardiovascular risk categories in two CORALreef phase 3 trials
Amsterdam University Medical Centers; University of Milan
ESC Congress 2026 Abstract, Oct 26, 2026, Open access
Presented at ESC Congress 2026
